Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Cancer
Shots:
- Sairopa to receive ~$40M and an additional $70M in near-term milestones for an option to obtain an exclusive license globally for ADU-1805 and other anti-SIRPα antibodies, ~$97.5M in success-based development milestone during the option period & an additional $465.0M upon achievement of specified clinical, commercial and net sales milestones along with royalties on net sales globally
- Upon the completion of the clinical studies, Exelixis get the right to exercise its option for an option exercise fee of $225M based upon an evaluation of a pre-specified clinical data package to be delivered by Sairopa
- The acquisition expands Exelixis’ clinical pipeline & also expands the potential clinical and commercial value of ADU-1805
Ref: Businesswire | Image: Exelixis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
